The quest to unlock the protective power of patient antibodies just got a $315.0M injection. Alchemab Therapeutics Ltd, which aims to keep people free of hard-to-treat diseases, has closed its Series A funding round.
The company is developing a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first methodology, employing three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Its engine is enabled through collaborations with patient representative groups and biobanks around the world, furthering its understanding of disease.
.png&w=3840&q=75)
